Hospital
Chca Womans Hospital LP
Chca Womans Hospital LP was paid $5.38M by Medicaid between Oct 2020 and Dec 2024, across 41 billing codes. Its largest line is 99284, emergency room visit (serious) — 64% of everything it billed.
33Billing provider infoCHCA WOMANS HOSPITAL LP
HOUSTON, TX 77054
HOUSTON, TX 77054
33aNPI1023065794assigned 05/28/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$5.38M
24GClaims60,093
24DCodes billed41
24AFirst – last monthOct 2020 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Texas
Rank by total paid#35 of 109
Median peer was paid$1.15M
This provider vs. median4.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 589 | $140K | |
| 2021 | 14,497 | $1.63M | |
| 2022 | 20,931 | $1.59M | |
| 2023 | 17,009 | $1.46M | |
| 2024incomplete | 7,067 | $553K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 64% | 8,322 | 7,705 | $3.47M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 6,529 | 6,328 | $1.06M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.9% | 579 | 567 | $102K |
| J7030 | Infusion, normal saline solution , 1000 cc | 1.6% | 1,299 | 1,189 | $86K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 1.6% | 1,143 | 1,019 | $83K |
| 93976 | 1.5% | 966 | 862 | $81K | |
| 76801 | 1.5% | 913 | 811 | $79K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.3% | 3,721 | 3,633 | $71K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.3% | 3,533 | 3,374 | $70K |
| 87634 | <1% | 1,141 | 1,121 | $48K | |
| 80053 | Comprehensive metabolic panel | <1% | 4,236 | 3,884 | $40K |
| 85027 | <1% | 7,426 | 6,778 | $32K |
29 more codes
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 396 | $25K |
| 81001 | <1% | 8,363 | $22K | |
| 84702 | <1% | 1,911 | $22K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,722 | $20K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 85 | $20K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,000 | $9K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 403 | $9K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 24 | $8K |
| 81025 | <1% | 1,393 | $7K | |
| 71045 | Radiologic examination, chest; single view | <1% | 307 | $5K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 916 | $4K |
| 83690 | <1% | 622 | $3K | |
| 86900 | <1% | 915 | $3K | |
| 86901 | <1% | 915 | $2K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 25 | $1K |
| 80076 | <1% | 208 | $1K | |
| 84030 | <1% | 106 | $1K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 13 | $866.52 |
| S3620 | Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) | <1% | 707 | $734.24 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 25 | $543.68 |
| 80306 | <1% | 42 | $372.01 | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 17 | $238.40 |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 38 | $236.03 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 12 | $229.72 |
| 83735 | <1% | 52 | $209.35 | |
| 86850 | <1% | 17 | $198.86 | |
| 82248 | <1% | 26 | $63.95 | |
| 86140 | <1% | 12 | $23.40 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMATHIEU, AKI (CFO)